Genetic Analysis Reports Strong Q2 2025 Growth
Genetic Analysis AS has shown significant growth in Q2 2025, driven by increased sales and strategic partnerships.
Sammanfattning
Genetic Analysis AS reports notable growth in Q2 2025 with a 34% increase in sales, strategic market entries, and successful capital raising efforts.
Genetic Analysis AS (GA) has reported a robust performance for the second quarter of 2025, highlighting a 34% increase in sales from the corresponding period last year. This growth, driven by strong sales of GA-map® reagent kits in the US, has resulted in an operating income of NOK 7.2 million, up from NOK 5.0 million in Q2 2024.
The company has successfully launched the GA-map® Dysbiosis Test in the Chinese Consumer Health market, in collaboration with Thalys Medical Technology Group. This move marks GA's strategic entry into the rapidly growing Chinese microbiome diagnostic market, tapping into the potential of personalized health solutions.
Financially, GA has demonstrated significant improvements, with a positive EBITDA of NOK 0.5 million for the quarter, a stark contrast to the negative NOK 3.4 million in Q2 2024. The net loss has also narrowed considerably to NOK 1.0 million, compared to NOK 4.8 million in the previous year.
In addition, GA completed a directed share issue of NOK 12.8 million, primarily subscribed by existing shareholders, including Bio-Rad Laboratories. This capital raise is set to accelerate commercialization efforts and support ongoing collaborations, notably with Ferring Pharmaceuticals and Pangea Laboratory for the US launch of the GA-map® MHI GutHealth test.
With these positive developments and a strengthened board of directors, including the appointment of Morten Jurs and Ove Öhman, GA is well-positioned for future growth. The company’s strategic initiatives and financial resilience suggest a promising outlook, making it a compelling consideration for investors.
Given the current trajectory and strategic positioning of GA in the microbiome diagnostics sector, the recommendation is to hold the stock. The company’s ongoing innovations and market expansions are likely to yield further value in the coming quarters.
Källa
Sammanfattning
Genetic Analysis CEO Ronny Hermansen notes a growing interest in their microbiome diagnostic products in various health sectors during the first half of 2025. The company reported an operating income of NOK 7.2 million in Q2 2025, with sales reaching NOK 5.9 million, marking a 34% increase from the previous year. The net loss for Q2 was NOK 1.0 million, an improvement from NOK 4.8 million the year before. EBITDA was positive at NOK 0.5 million, compared to a negative NOK 3.4 million in 2024. Total assets were valued at NOK 55.0 million, and the equity ratio stood at 59.5%. Key developments included the launch of the GA-map® Dysbiosis Test in China and the completion of a capital raise supported by major shareholders. The company also developed the GA-map® MHI GutHealth test in collaboration with Ferring Pharmaceuticals, preparing for a US launch. A directed share issue raised NOK 12.8 million to support further collaborations and sales initiatives. Changes in the board included the appointment of Morten Jurs as Chairman and Ove Öhman as a new member. A subsequent offering resulted in NOK 4.1 million raised from subscribed shares.
